Local view for "http://purl.org/linkedpolitics/eu/plenary/2004-12-02-Speech-4-109"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20041202.8.4-109"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
".
We welcome the adoption of this resolution, particularly given that most of the proposals that we tabled to improve the joint resolution were adopted. They were as follows:
Calls on the Commission and the Member States to contribute at least EUR 1 billion, on a sustained basis, to the Global Fund to fight HIV/AIDS, tuberculosis and malaria;
Calls on the European pharmaceutical industry to set aside a significant proportion of its resources for anti-infective medicines and other essential medicines; calls on Sanofi-Aventis, for example, the largest European pharmaceutical group, to start researching this disease, instead of dispersing its team of expert researchers in this field;
Calls on the Commission to draw up a proposal aimed at safeguarding the public interest more effectively when it comes to the orientation, research, development and production of medicines, at cutting prices and medical spending on public health services, and at guaranteeing the right of universal access to medical treatment and essential medicines;
Calls on the Commission to oppose – both within the World Trade Organisation and in its bilateral relations – the insistence by the USA in its bilateral agreements with developing countries that those countries renounce the right to import the generics that they need to protect their citizens’ public health."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples